



PRÓ-REITORIA DE PESQUISA E PÓS-GRADUAÇÃO  
MESTRADO EM CIÊNCIAS DA SAÚDE

LUDMILA PANTAROTO LIMA RIBEIRO

ANÁLISE DA *DYSPHANIA AMBROSIOIDES* COMO AGENTE  
PROTETOR DA PERDA DE MASSA ÓSSEA



PRÓ-REITORIA DE PESQUISA E PÓS-GRADUAÇÃO  
MESTRADO EM CIÊNCIAS DA SAÚDE

LUDMILA PANTAROTO LIMA RIBEIRO

**ANÁLISE DA *DYSPHANIA AMBROSIOIDES* COMO AGENTE  
PROTETOR DA PERDA DE MASSA ÓSSEA**

Dissertação apresentada Pró-Reitoria de Pesquisa e Pós-Graduação, Universidade do Oeste Paulista, como parte dos requisitos para obtenção do título de mestre. - Área de concentração: Ciências da Saúde

Orientador:  
Prof. Dr. Wilson Romero Nakagaki

Presidente Prudente - SP  
2023

**Catálogo Internacional na Publicação (CIP)**

616.362  
R484a

Ribeiro, Ludmila Pantaroto Lima

Análise da dysphania ambrosioides como agente protetor da perda de massa óssea \ Ludmila Pantaroto Lima Ribeiro; orientador Wilson Romero Nakagaki. -- Presidente Prudente, 2023.

61 f.: il.

Dissertação (Mestrado em Ciências da Saúde) - Universidade do Oeste Paulista - Unoeste, Presidente Prudente, SP, 2023.

Bibliografia.

1. Osso. 2. Densidade óssea. 3. Glicocorticoide. 4. *Dysphania ambrosioides*. I. Nakagaki, Wilson Romero, orient. II. Título.

**LUDMILA PANTAROTO LIMA RIBEIRO**

**ANÁLISE DA *DYSPHANIA AMBROSIOIDES* COMO AGENTE  
PROTETOR DA PERDA DE MASSA ÓSSEA**

Dissertação apresentada Pró-Reitoria de Pesquisa e Pós-Graduação, Universidade do Oeste Paulista, como parte dos requisitos para obtenção do título de mestre. Área de Concentração: Ciências da Saúde.

Presidente Prudente, 24 de março de 2023.

**BANCA EXAMINADORA**

---

Orientador Prof. Dr. Wilson Romero Nakagaki  
Universidade do Oeste Paulista – Unoeste  
Presidente Prudente – SP

---

Profa. Dra. Lizziane Kretli Winkelstroter Eller  
Universidade do Oeste Paulista – Unoeste  
Presidente Prudente – SP

---

Profa. Dra. Flávia da Ré Guerra  
Universidade Federal de Alfenas – Unifal - MG  
Alfenas – MG

## **DEDICATÓRIA**

Esta pesquisa é dedicada a Deus, causa primordial de todas as coisas. Ao meu filho Joaquim, afim de incentivar a importância da educação em nossas vidas. Aos meus familiares que sempre me apoiaram durante esta jornada, e em especial ao meu marido Evandro que permaneceu ao meu lado incentivando a buscar minha melhor versão. Essa conquista é para vocês.

## **AGRADECIMENTOS**

Agradeço a Deus a chance de mais uma experiência de aprendizado em minha vida. A todos os profissionais do programa de mestrado em ciências da saúde pelo incentivo na busca de aprimoramento acadêmico-científico. Em especial ao meu orientador, o Professor Dr. Wilson Romero Nakagaki por todo apoio e direcionamento ao longo do percurso, compartilhando seus conhecimentos para que fosse possível a realização deste sonho. Ao professor Me. Marcos Alberto Zocoler, a Me. Lucimeire Fernandes Correia e ao graduando Adriano Junqueira de Moraes, por todo o apoio e orientação durante as análises de farmacologia. E aos professores Dra. Ana Claudia Pacheco Santos, Dr. Luis Alberto Gobbo, Me. Mateus Dassie Maximino, Dra. Lizziane Kretli Winkelströter Eller e Dr. Décio Gomes de Oliveira, agradeço por todo apoio direto e indireto pelo qual contribuíram de forma essencial para a realização deste estudo. Aos colaboradores do biotério de experimentação animal Sidmar de Lima Martins e veterinária Gracielle Vieira Gonçalves, por todo o apoio e disponibilidade constante. E a professora do curso de nutrição Dra. Sabrina Alves Lenquiste que me direcionou no início desta decisão. Gratidão a todos vocês.

*“Causa estranheza àqueles que não estão familiarizados com o amor dedicado aos animais e as plantas, causa estranheza àqueles que não entendem que na terra existem outras formas de vida.” (Maura Watan)*

## RESUMO

### **Análise da *Dysphania ambrosioides* como agente protetor da perda de massa óssea**

Os glicocorticoides apresentam efeitos adversos que podem desencadear a perda de densidade mineral óssea. Há evidências que demonstram que a *Dysphania ambrosioides* pode prevenir a perda de massa óssea. O objetivo do trabalho foi analisar possíveis efeitos do consumo da *Dysphania ambrosioides* em ossos de ratas submetidas a indução de perda de densidade mineral óssea por uso de dexametasona durante 7 semanas. Foram utilizadas 40 ratas Wistar distribuídas em quatro grupos: grupo controle (CT), grupo dexametasona (Dexa), grupo dexametasona ambrosioides 25 mg/kg (Ambro1) e grupo dexametasona ambrosioides 500 mg/kg (Ambro2). Foram realizadas análises qualitativas e quantitativas no extrato bruto hidroalcoólico de *Dysphania ambrosioides*, sendo identificado a presença de saponinas 0,618 µg/ml, flavonoides 2,174 µg/ml, taninos 63,44 µg/ml e alcaloides 0,107 µg/ml. A dexametasona foi aplicada duas vezes na semana, enquanto a *Dysphania ambrosioides* foi administrada diariamente. O controle de peso semanal apresentou perda ponderal nos grupos que receberam a dexametasona, com atenuação da perda em Ambro2. Após a eutanásia dos animais, foram realizadas análise das propriedades estruturais e materiais e análise de Raman dos fêmures. No ensaio mecânico o grupo CT apresentou maiores valores de força máxima comparado aos grupos Dexa e Ambro2, e foi similar estatisticamente com os três grupos tanto para a deformação absoluta quanto para a rigidez estrutural. O grupo Dexa foi menos resistente à aplicação de força em relação ao grupo Ambro1, o qual foi similar ao grupo CT. O CT apresentou maior valor para a tensão máxima em relação aos grupos Dexa e Ambro2, e similar em relação ao grupo Ambro1. O grupo Ambro1 suportou maior tensão comparado aos grupos Dexa e Ambro2. O CT e Ambro1 apresentaram maiores valores de módulo elástico, o grupo CT apresentou diferença em relação aos grupos Dexa e Ambro2 e o grupo Ambro1 demonstrou diferença quando comparado aos grupos Dexa e Ambro2. Na análise de Raman a razão 430/1270 não apresentou diferença estatística entre os quatro grupos. A razão 960/1660 o grupo CT apresentou diferença entre os demais grupos, e o grupo Dexa apresentou diferença entre o Ambro2. A razão 1070/1660 foi observado diferença estatística entre o grupo CT e os demais grupos. Assim, foi possível observar que a *Dysphania ambrosioides* possui efeitos promissores relacionados ao aumento da resistência óssea mediante a indução de osteoporose por glicocorticoides.

**Palavras-chave:** Osso; Densidade óssea; Glicocorticoide; *Dysphania ambrosioides*.



## ABSTRACT

### **Analysis of *Dysphania ambrosioides* as a protective agent of bonemass loss**

Glucocorticoids have adverse effects that can trigger loss of bone mineral density. There is evidence that *Dysphania ambrosioides* can prevent bone loss. The aim of this study was to analyze possible effects of *Dysphania ambrosioides* consumption on bones of female rats submitted to induction of loss of bone mineral density by using dexamethasone for 7 weeks. Forty female Wistar rats were divided into four groups: control group (CT), dexamethasone group (Dexa), dexamethasone ambrosioides 25 mg/kg group (Ambro1) and dexamethasone ambrosioides 500 mg/kg (Ambro2) group. Qualitative and quantitative analyzes were performed on the crude hydroalcoholic extract of *Dysphania ambrosioides*, identifying the presence of saponins 0.618 µg/ml, flavonoids 2.174 µg/ml, tannins 63.44 µg/ml and alkaloids 0.107 µg/ml. Dexamethasone was applied twice a week, while *Dysphania ambrosioides* was administered daily. Weekly weight control showed weight loss in the groups that received dexamethasone, with loss attenuation in Ambro2. After the euthanasia of the animals, structural and material properties were analyzed and Raman analysis of the femurs. In the mechanical test, the CT group showed higher values of maximum force compared to the Dexa and Ambro2 groups, and was statistically similar with the three groups both for absolute strain and for structural stiffness. The Dexa group was less resistant to force application than the Ambro1 group, which was similar to the CT group. CT showed a higher value for maximum tension in relation to the Dexa and Ambro2 groups, and similar in relation to the Ambro1 group. The Ambro1 group withstood greater tension compared to the Dexa and Ambro2 groups. CT and Ambro1 showed higher elastic modulus values, the CT group showed a difference in relation to the Dexa and Ambro2 groups, and the Ambro1 group showed a difference when compared to the Dexa and Ambro2 groups. In the Raman analysis, the 430/1270 ratio showed no statistical difference between the four groups. The ratio 960/1660, the CT group showed a difference between the other groups, and the Dexa group showed a difference between the Ambro2. The 1070/1660 ratio showed a statistical difference between the CT group and the oand hus, it was possible to observe that *Dysphania ambrosioides* has promising effects related to increased bone strength through the induction of osteoporosis by glucocorticoids.

**Keywords:** Bone; Bone density; Glucocorticoid; *Dysphania ambrosioides*.

## LISTA DE SIGLAS

Ambro1	– Grupo <i>Dexametasona Ambrosioides 1</i>
Ambro2	– Grupo <i>Dexametasona Ambrosioides 2</i>
CEUA	– Comissão de Ética no Uso de Animais
CH <sub>2</sub>	– Hidrocarboneto
COBEA	– Colégio Brasileiro de Experimentação Animal
CSMI	– Momento de Inércia de Secção Transversal
CT	– Grupo Controle
Dexa	– Grupo Dexametasona
DMO	– Densidade Mineral Óssea
GC	– Glicocorticoides
LB	– Liberman - Burchard
OMS	– Organização Mundial da Saúde
RENISUS	– Relação Nacional de Plantas Medicinais de Interesse do SUS
UNICAMP	– Universidade Estadual de Campinas
UNOESTE	– Universidade do Oeste Paulista
V <sub>1</sub> CO <sub>3</sub> <sup>2-</sup>	– Carbonato
V <sub>1</sub> PO <sub>4</sub> <sup>3-</sup>	– Fosfato V1
V <sub>2</sub> PO <sub>4</sub> <sup>3-</sup>	– Fosfato V2
V <sub>4</sub> PO <sub>4</sub> <sup>3-</sup>	– Fosfato V4
vC-C	– Hidroxiprolina de colágeno

## LISTA DE FIGURAS

Figura 1	– (A) Coleta da <i>Dysphania ambrosioides</i> . (B) secagem em estufa com circulação e renovação de ar. (C) Trituração em moinho de facas.	16
Figura 2	– Teste mecânico de flexão de três pontos de fêmures.....	21
Figura 3	– Evolução do peso dos animais do início do experimento ao dia da eutanásia.....	24
Figura 4	– Propriedades estruturais de força máxima, deformação absoluta na força máxima e rigidez extrínseca.....	25
Figura 5	– Propriedades materiais de tensão máxima, deformação relativa na tensão máxima e módulo elástico.....	26
Figura 6	– Bandas do espectro de Raman 430, 580, 872, 960, 10700, 1272, 1450, 1660.....	28
Figura 7	– Razões do espectro de Raman 430/1272, 960/1660 e 1070/1660.....	29

## LISTA DE TABELAS

Tabela 1 - Ensaio de identificação dos metabólitos secundários de <i>Dysphania ambrosioides</i> .....	23
---	----

**SUMÁRIO**

ARTIGO CIENTÍFICO – Análise da <i>Dysphania ambrosioides</i> como agente protetor da perda de massa óssea .....	13
Introdução .....	14
Materiais e Métodos .....	15
Resultados .....	23
Discussão.....	29
Conclusão .....	34
Referências .....	34
ANEXOS .....	39
ANEXO A - Normas de Submissão Life Sciences.....	40
ANEXO B - Aprovação do comitê de ética.....	61

## REFERÊNCIAS

1. Carvalho LC, Caiado NDBBC, Mendes AV, Souza AB, Júnior JAf, Franzoni I, et al. As principais considerações clínicas da osteoporose para a saúde pública. *Research, society and development*. 2022;11(7).
2. Faria LP. Efeito do alendronato, da dexametasona e da associação de ambos sobre a osteoclastogênese: um estudo in vitro. [tese]. São Paulo: Faculdade de Odontologia, 2021. doi:10.11606/T.23.2021.tde-27102021-123034.
3. Paccou J, Cortet B. Osteoporosis: generalidades, estratégia diagnóstica. *Emc - aparato locomotor*. 2022;55(2):1–10.
4. Gerino JA, Oliveira Neto EF, Ferreira LM, Cangussu MCT, Sardinha SCS, Cavalcante WC. Uso de corticoides por cirurgias bucomaxilofaciais do Brasil. *J health biol sci*. 2020;1–5.
5. Aguiar IA, Giacomini RL, Lucinda LMF, Barreiros LL, Fontes LBA, Nonato IA, et al. A ação dos glicocorticoides no metabolismo ósseo levando a osteoporose. *Revista científica unifagoc - saúde*. 2018;3(2):30–7.
6. Leboff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, et al. The clinician's guide to prevention and treatment of osteoporosis. *Osteoporos int*. 2022;33(10):2049–102.
7. Khajuria DK, Razdan R, Mahapatra DR. Medicamentos para o tratamento da osteoporose: revisão. *Rev bras reumatol*. 2011;51(4):372–82.
8. Radominski SC, Bernardo W, Paula AP, Albergaria BH, Moreira C, Fernandes CE, et al. Diretrizes brasileiras para o diagnóstico e tratamento da osteoporose em mulheres na pós-menopausa. *Rev bras reumatol*. 2017;57:s452–66.
9. Matuoka JY. Análise econômica do denosumabe e dos bisfosfonatos no tratamento de pacientes com metástase óssea. [tese]. São Paulo: Escola de Enfermagem; 2019. doi:10.11606/T.7.2019.tde-23022021-095026.
10. Zago I. Vinte e dois anos de pesquisa sobre plantas medicinais: uma análise cienciométrica. 2018;3:1–17.
11. Dresch RR, Libório YB, Czermainski SBC. Compilação de levantamentos de uso de plantas medicinais no rio grande do sul. *Physis*. 2021;31:e310219.
12. Pinheiro Neto VF, Ribeiro RM, Morais CS, Campos MB, Vieira, Guerra PC, et al. *Chenopodium ambrosioides* as a bone graft substitute in rabbits radius fracture. *Bmc complementary and alternative medicine*. 2017;17(1):350.
13. Santos ABN, Araújo MP, Sousa RS, Lemos JR. Plantas medicinais conhecidas na zona urbana de cajueiro da praia, piauí, nordeste do Brasil. *Rev bras plantas med*. Junho de 2016;18:442–50.
14. Carneiro DTO. Extrato da folha de *Chenopodium ambrosioides* Linn (mastruz) atenua a perda óssea alveolar na periodontite experimental em ratos. 9 mar. 2020 [citado 23 de fevereiro de 2023]; disponível em: <http://www.repositorio.ufc.br/handle/riufc/59321>

15. Penha ES, Lacerda-Santos R, De Medeiros LADM, Araújo Rosendo R, Dos Santos A, Fook MVL, et al. Avaliação da ação analgésica do extrato hidroalcoólico de *Chenopodium ambrosioides* L. Em ensaios pré-clínicos. *Microsc res tech*. 2012; 1(10):73–82.
16. Reyes-Becerril M, Angulo C, Sanchez V, Vázquez-Martínez J, López MG. Antioxidant, intestinal immune status and anti-inflammatory potential of *Chenopodium ambrosioides* L. In fish: in vitro and in vivo studies. *Fish & shellfish immunology*. 2019;86:420–8.
17. Limaverde PW, Campina FF, Cunha FAB, Crispim FD, Figueredo FG, Lima LF, et al. Inhibition of the tetK efflux-pump by the essential oil of *Chenopodium ambrosioides* L. And  $\alpha$ -terpinene against *Staphylococcus aureus* IS-58. *Food and chemical toxicology*. 2017;109:957–61.
18. Almeida Bezerra JW, Rodrigues Costa A, Freitas Ma, Rodrigues FC, Souza MA, Silva ARP, et al. Chemical composition, antimicrobial, modulator and antioxidant activity of essential oil of *Dysphania ambrosioides* (L.) Mosyakin & Clemants. *Comp Immunol Microbiol Infect Dis*. 2019;65:58–64.
19. Da Silva FMA, Da Silva KPA, De Oliveira LPM, Costa EV, Koolen HH, Pinheiro MLB, et al. Flavonoid glycosides and their putative human metabolites as potential inhibitors of the SARS-CoV-2 main protease (M<sup>pro</sup>) and RNA-dependent RNA polymerase (RdRp). *Mem Inst Oswaldo Cruz*. 2020;115:e200207.
20. Soares CD, Carvalho MGF, Carvalho RA, Trindade SRP, Rêgo ACM, Araújo-Filho I, et al. *Chenopodium ambrosioides* L. Extract prevents bone loss. *Acta Cir Bras*. 2015;30(12):812–8.
21. Trindade GD, Maia Filho ALM, Rodrigues JS, Ferreira DCL, De Araújo KS. Efeitos de extrato em gel de *Chenopodium ambrosioides* L. (mastruz) no tratamento de lesões ósseas de ratas osteoporóticas. *Revista eletrônica acervo odontológico*. 2021;3:e6260–e6260.
22. Abreu PAP, Onofre SB. Atividade antimicrobiana dos extratos de *Baccharis dracunculifolia* D. C. (Asteraceae). *Sabios-Revista de Saúde e Biologia* [internet]. 22 de dezembro de 2010 [citado 23 de fevereiro de 2023];5(2). Disponível em: <https://revista.grupointegrado.br/revista/index.php/sabios/article/view/669>
23. Menezes Filho ACP, Castro CFS. Classes fitoquímicas de metabólitos secundários em extratos etanólicos foliares de espécies do cerrado brasileiro. *Revista Saúde & Ciência Online*. 2019;8(1):45–61.
24. Matos FJA. Introdução à fitoquímica experimental (3ª edição). Vol. 3. ed., Fortaleza: UFC; 2009.
25. Oliveira MAC, Albuquerque MM, Xavier HS, Strattmann RR, Grangeiro Júnior S, Queiroz AT. Desenvolvimento e validação de metodologia para quantificação de alcalóides totais como berberina em fitoterápico contendo *Berberis vulgaris* L. *Rev Bras Farmacogn*. 2006;16:357–64.
26. Gonçalves RP, Maldaner G, Mariño P, Menezes AP. Avaliação fitoquímica qualitativa das folhas da pitangueira (*Eugenia uniflora* L.). *Anais Congrega MIC* - 2021;17:275–80.
27. Lozano M, Ticona E, Carrasco C, Flores Y, Almanza GR. Cuantificación de

saponinas em resíduos de quinua real *Chenopodium quinoa* Willd. *Revista Boliviana de Química*. 2012;29(2):131–8.

28. Gomes DS, Melo RJ, Ikeda R, Hollais AW, Rodrigues FMD, Rodrigues A. Comparação do teor de flavonoides de *Calendula officinalis* em cultivo orgânico em diferentes estações climáticas. *Diálogos Interdisciplinares*. 2018;7(3):75–89.

29. Sakanaka S, Tachibana Y, Okada Y. Preparation and antioxidant properties of extracts of Japanese persimmon leaf tea (*Kakinoha-cha*). *Food Chemistry*. 2005;89(4):569–75.

30. Poyer A, Schaefer L, Teixeira SD, Rocha RDC. Obtenção de taninos a partir do extrato hidroalcoólico de folhas e flores de *Lippia alba*. *Synergismus Scientifica UTFPR*. 2015;10(1):140–51.

31. Singleton VL, Rossi JA. Colorimetry of total phenolics with phosphomolybdic-phosphotungstic acid reagents. *Am J Enol Vitic*. 1965;16(3):144–58.

32. Pereira WS, Da Silva GP, Vigliano MV, Leal NRF, Pinto FA, Fernandes DC, et al. Anti-arthritic properties of crude extract from *Chenopodium ambrosioides* L. Leaves. *J Pharm Pharmacol*. 2018;70(8):1078–91.

33. Lucinda LMF, Vieira BJ, Salvador PA, Oliveira TT, Peters VM, Reis JP, et al. Efeito do extrato de *Ginkgo biloba* L., *Ginkgoaceae*, na osteoporose induzida em ratos Wistar. *Rev Bras Farmacogn*. 2010;20:429–34.

34. Maia JPC. Suplementação com quercetina reduz a dislipidemia e a esteatose hepática em ratos alimentados com dieta obesogênica. Supplement with quercetin reduces dyslipidemic and hepatic steatosis in rats fed with obesogenic diet [internet]. 9 dez. 2019 [citado 8 fev. 2023]; Disponível em: <http://bdtd.unoeste.br:8080/jspui/handle/jspui/1304>

35. Oliveira JAGT, Neves MD, Sampaio GFS, Constantino CJL, Nakagaki WR. Analysis of the effects of curcumin and symbiotic consumption on bones of rats submitted to the use of dexamethasone. *Life Sciences*. 2022;304:120690.

36. Akhter M, Cullen D, Gong G, Recker R. Bone biomechanical properties in prostaglandin EP1 and EP2 knockout mice. *Bone*. 2001;

37. Nakagaki WR, Bertran CA, Matsumura CY, Santo-Neto H, Camilli JA. Mechanical, biochemical and morphometric alterations in the femur of mdx mice. *Bone*. 2011;48(2):372–9.

38. Turner CH, Burr DB. Basic biomechanical measurements of bone: a tutorial. *Bone*. 1993;14(4):595–608.

39. Ciubuc JD, Manciu M, Maran A, Yaszemski MJ, Sundin EM, Bennet KE, et al. Raman spectroscopic and microscopic analysis for monitoring renal osteodystrophy signatures. *Biosensors*. 2018;8(2):38.

40. Soares IAL. Universidade Federal de Campina Grande centro de ciências e tecnologia programa de pós-graduação em engenharia de processos. 2021;

41. Soares IAL. Obtenção de extratos de folhas de mastruz (*Chenopodium ambrosioides* L.): estudo experimental e otimização do processo. Obtaining mastruz leaf extracts (*Chenopodium ambrosioides* L.): experimental study and process



- optimization [internet]. 9 mar. 2021 [citado 22 mar. 2023]; disponível em: <http://dspace.sti.ufcg.edu.br:8080/jspui/handle/riufcg/19201>
42. Dias HR. Substâncias antioxidantes em alimentos e seus benefícios para a saúde: uma revisão bibliográfica. 2020 [citado 9 de fevereiro de 2023]. Disponível em: <http://bia.ifpi.edu.br:8080/jspui/handle/123456789/571>
43. Tauchen J, Huml I, Bortl I, Doskocil I, Jarosova V, Marsik P, et al. Screening of medicinal plants traditionally used in peruvian amazon for *in vitro* antioxidant and anticancer potential. *Natural product research*. 2019;33(18):2718–21.
44. Ramana KV, Reddy ABM, Majeti NVRK, Singhal SS. Therapeutic potential of natural antioxidants. *Oxidative medicine and cellular longevity*. 2018;2018:e9471051.
45. Martins GV, Morais SM, Alves DR, Vieira-Araujo FM. Estudo químico e avaliação das atividades antioxidante, anti-acetilcolinesterase e anti-leishmanial de extratos de *jatropha gossypifolia* L. (pião roxo). *Revista Virtual de Química* 2018;10(1). Disponível em: <https://rvq-sub.sbq.org.br/index.php/rvq/article/view/1890>
46. Mundy GR. Osteoporosis and inflammation. *Nutrition reviews*. 2007;65(suppl\_3):s147–51.
47. Sá RD. Estudo farmacognóstico de *chenopodium ambrosioides* L. (chenopodiaceae). [Dissertação] Recife: Universidade Federal de Pernambuco, 2013. Disponível em: <https://repositorio.ufpe.br/bitstream/123456789/10715/1/disserta%c3%a7%c3%a3o%20rafaela%20damasceno%20s%c3%a1.pdf>.
48. Pang JL, Ricupero DA, Huang S, Fatma N, Singh DP, Romero JR, et al. Differential activity of kaempferol and quercetin in attenuating tumor necrosis factor receptor family signaling in bone cells. *Biochemical pharmacology*. 14 de março de 2006;71(6):818–26.
49. Clarke BL, Khosla S. Physiology of bone loss. *Radiologic clinics of north america*. 2010;48(3):483–95.
50. Abdulkader OM, Sharaf AEA, Fouda HM, Elhaw MH. Phytoconstitutes investigation of *chenopodium ambrosioides* linn. And gas chromatography with mass spectroscopy material analysis. *Materials today: proceedings*. 2022;61:992–7.
51. Alcantara EH, Shin MY, Sohn HY, Park YM, Kim T, Lim JH, et al. Diosgenin stimulates osteogenic activity by increasing bone matrix protein synthesis and bone-specific transcription factor runx2 in osteoblastic mc3t3-e1 cells. *The Journal of Nutritional Biochemistry*. 2011;22(11):1055–63.
52. Wattel A, Kamel S, Mentaverri R, Lorget F, Prouillet C, Petit JP, et al. Potent inhibitory effect of naturally occurring flavonoids quercetin and kaempferol on *in vitro* osteoclastic bone resorption. *Biochemical Pharmacology*. 2003;65(1):35–42.
53. Gobbo-Neto I, Lopes NP. Plantas medicinais: fatores de influência no conteúdo de metabólitos secundários. *Quím Nova*. 2007;30:374–81.
54. Seene T, Kaasik P, Pehme A, Alev K, Riso EM. The effect of glucocorticoids on the myosin heavy chain isoforms' turnover in skeletal muscle. *The Journal of Steroid Biochemistry and Molecular Biology*. 2003;86(2):201–6.
55. Araujo JES, Barreto TO, Filho JERM, Santos MRV DOS, Quintans-Junior LJ,

Barreto AS. Efeitos do exercício de resistido sobre a homeostase da glicose e ativação da mtor em ratos tratados por dexametasona. RBPFEEX - Revista Brasileira de Prescrição e Fisiologia do Exercício. 2021;15(96):163–72.

56. Araújo LCR, Lins MA, Lima GR, Moreschi ARC, Lima ES, Hanan SA, et al. Atividade do óleo de copaíba sobre radicais livres formados durante a resposta inflamatória / copaíba oil's activity on free radicals during the inflammatory response. Brazilian Journal of Development. 2020;6(7):53538–53.

57. Rosa RC, Rodrigues WF, Miguel CB, Cardoso FAG, Espindula AP, Oliveira CJF, et al. Consumo crônico de álcool afeta negativamente o osso de ratos jovens. Acta ortop bras. 2019;27:321–4.

58. Monzote I, Montalvo AM, Almanonni S, Scull R, Miranda M, Abreu J. Activity of the essential oil from chenopodium ambrosioides grown in cuba against leishmania amazonensis. Chemotherapy. 2006;52(3):130–6.

59. Zavala R, Herrera J, Lara AS, Garzon-Cortes VDL. Acute toxicity evaluation of an alcoholic extract of epazote (chenopodium ambrosioides) leaves/evaluación de la toxicidad aguda de un extracto alcohólico de hojas de epazote (chenopodium ambrosioides)/avaliacao da toxicidade aguda de um extrato alcoolico de folhas de mastruz. Spei Domus. 2016;12(24):31–9.

60. Hart NH, Nimphius S, Rantalainen T, Ireland A, Siafarikas A, Newton RU. Mechanical basis of bone strength: influence of bone material, bone structure and muscle action. J Musculoskelet Neuronal Interact. 2017;17(3):114–39.

61. Tenius FP, Biondo-Simões MLP, Ioshii SO. Efeitos do uso crônico da dexametasona na cicatrização de feridas cutâneas em ratos. An Bras Dermatol. 2007;82(2):141–9.

62. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. Vegf couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med. 1999;5(6):623–8.

**ANEXOS**

## **ANEXO A – Normas Revista *LIFE SCIENCES***

### **YOUR PAPER YOUR WAY**

We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article. To find out more, please visit the Preparation section below.

### **INTRODUCTION**

Life Sciences is an international journal publishing articles that emphasize the molecular, cellular, and functional basis of therapy. All articles are rigorously reviewed. The Journal favors publication of full-length papers where modern scientific technologies are used to explain molecular, cellular and physiological mechanisms. Articles that merely report observations are rarely accepted. Articles should be written at a level accessible to readers who are non-specialists in the topic of the article themselves, but who are interested in the research. The Journal welcomes reviews on topics of wide interest to investigators in the life sciences. We particularly encourage submission of focused reviews containing high-quality artwork and mechanistic diagrams.

### **IMPORTANT INFORMATION**

- Submission of a paper will be held to imply that the manuscript contains original unpublished work and is not being submitted for publication elsewhere.
- Manuscripts should present novel findings addressing significant biological questions. Studies that fail to do so may be rejected without review.
- Quantitative conclusions must be based on truly quantitative methods.
- Life Sciences does not publish work on the actions of biological extracts of unknown chemical composition. Compounds studied must be of known chemical structure and concentration.
- The study must be reproducible; materials used must be available to other researchers so they can repeat the experiment.

For more details on how to write a world class paper, please visit our Pharmacology Author Resources page.

**Please include word count and figure/table count on the cover page of your manuscript.**

**Authors are encouraged to submit video material or animation sequences** to support and enhance your scientific research. For more information please see the paragraph on video data below.

### **Types of article**

- Original research articles
- Reviews

### **Submission Checklist**

You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

### **Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:

- Institutional E-mail address
- Full postal address

Every author offers the institutional E-mail address.

All necessary files have been uploaded:

Manuscript:

- Include keywords
  - All figures (include relevant captions)
  - All tables (including titles, description, footnotes)
  - Ensure all figure and table citations in the text match the files provided
  - Indicate clearly if color should be used for any figures in print
- Graphical Abstracts / Highlights files (where applicable)
- Supplemental files (where applicable)

#### Further considerations

- Manuscript has been 'spell checked' and 'grammar checked'
- All references mentioned in the Reference List are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)
- A competing interests statement is provided, even if the authors have no competing interests to declare
- Journal policies detailed in this guide have been reviewed
- Referee suggestions and contact details provided, based on journal requirements For further information, visit our Support Center.

### **BEFORE YOU BEGIN**

#### Ethics in publishing

Please see our information on Ethics in publishing.

#### **Studies in humans and animals**

If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms sex and gender should be used correctly.

Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed. All animal experiments should comply with the ARRIVE guidelines and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Research Council's Guide for the Care and Use of Laboratory Animals and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where

appropriate, the influence (or association) of sex on the results of the study.

### **Conflict of Interest Policy**

The Journal requires full disclosure of all potential conflicts of interest. At the end of the manuscript text, under a subheading "Conflict of Interest statement", all authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. If there are no conflicts of interest, the authors should state: "The authors declare that there are no conflicts of interest." See also <https://www.elsevier.com/conflictsofinterest>. A signed Conflict of Interests Policy Form is required upon submission. The corresponding author is responsible for completing the form, and signing it on behalf of all authors.

### **Submission declaration and verification**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check.

### **Preprint posting on SSRN**

In support of Open Science, this journal offers its authors a free preprint posting service. Preprints provide early registration and dissemination of your research, which facilitates early citations and collaboration. During submission to Editorial Manager, you can choose to release your manuscript publicly as a preprint on the preprint server SSRN once it enters peer-review with the journal. Your choice will have no effect on the editorial process or outcome with the journal. Please note that the corresponding author is expected to seek approval from all co-authors before agreeing to release the manuscript publicly on SSRN.

You will be notified via email when your preprint is posted online and a Digital Object Identifier (DOI) is assigned. Your preprint will remain globally available free to read whether the journal accepts or rejects your manuscript. For more information about posting to SSRN, please consult the SSRN Terms of Use and FAQs.

### **Use of inclusive language**

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. When coding terminology is used, we recommend to avoid offensive or exclusionary terms such as "master", "slave", "blacklist" and "whitelist". We suggest using alternatives that are more appropriate and (self-) explanatory such as "primary", "secondary", "blocklist" and "allowlist". These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

### **Author contributions**

For transparency, we encourage authors to submit an author statement file outlining their individual contributions to the paper using the relevant CRediT roles: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing. Authorship restatements should be formatted with the names of authors first and CRediT role(s) following. More details and an example.

### **Authorship**

All authors listed on your paper must have made significant contributions to the



study. To ensure clarity, you are required upon submission to enter the specific details of each author's contribution, which must substantiate the inclusion of each person on the manuscript. This information is required to be filled in on the Conflict of Interests Policy and Author Statement Form.

### **Changes to authorship**

Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

### **Copyright**

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement. Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases. For gold open access articles: Upon acceptance of an article, authors will be asked to complete a 'License Agreement' (more information). Permitted third party reuse of gold open access articles is determined by the author's choice of user license. As an author

you (or your employer or institution) have certain rights to reuse your work. More information. Elsevier supports responsible sharing Find out how you can share your research published in Elsevier journals.

### **Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement, it is recommended to state this.

### **Open access**

Please visit our Open Access page for more information. Elsevier Researcher Academy Researcher Academy is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

### **Language (usage and editing services)**

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's Author Services.

### **Submission**

Submission to this journal proceeds totally online. Use the following guidelines to prepare your article. Via the homepage of this journal (<https://www.elsevier.com/journals>) you will be guided stepwise through the creation and uploading of the various files. The system automatically converts source files to a single Adobe Acrobat PDF version of the article, which is used in the peer-review process. Please note that even though manuscript

source files are converted to PDF at submission for the review process, these source files are needed for further processing after acceptance. All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail and via the author's page in Editorial Manager, removing the need for a hard-copy paper trail.

For any queries please visit our Support Center. Suggesting reviewers

Please submit the names and institutional e-mail addresses of several potential reviewers.

You should not suggest reviewers who are colleagues, or who have co-authored or collaborated with you during the last three years. Editors do not invite reviewers who have potential competing interests with the authors. Further, in order to provide a broad and balanced assessment of the work, and ensure scientific rigor, please suggest diverse candidate reviewers who are located in different countries/ regions from the author group. Also consider other diversity attributes e.g. gender, race and ethnicity, career stage, etc. Finally, you should not include existing members of the journal's editorial team, of whom the journal are already aware.

## **PREPARATION**

For questions about the editorial process (including the status of manuscripts under review) or for technical support on submissions, please visit our Support Center.

## **NEW SUBMISSIONS**

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.

As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

## *References*

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/ book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

### *Formatting requirements*

There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions.

If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes.

Divide the article into clearly defined sections.

*Figures and tables embedded in text.* Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file. The corresponding caption should be placed directly below the figure or table.

### **Peer review**

This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the editor has an interest. Any such submission is subject to all of the journal's usual procedures, with peer review handled independently of the relevant editor and their research groups. More information on types of peer review.

## Language

Please write your text in good English (American or British usage is accepted, but nota mixture of these). For language assistance, please see Language Services, above. Use decimal points (not decimal commas); use a space for thousands (10 000 and above).

### *Use of word processing software*

Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

## Organization of the manuscript

Beginning with the first page, present your manuscript in the order below:

1. Title: First letter capitalized, subsequent letters in lower case. Avoid abbreviations.2a. Names of all authors.
- 2b. Affiliations of all authors. If necessary, use superscripted lowercase letters after the author's name to distinguish affiliations.
3. Author to whom proofs and correspondence should be sent, including name, mailing address, telephone and fax numbers, and e-mail address.
4. A structured abstract has to be submitted for research papers (not for reviews) of no more than 250 words. The following headings must be used: Aims: Main methods: Key findings: Significance:
5. Key words for indexing purposes (a maximum of six can be entered). In addition to key words from the title, please suggest other terms that help define the study. We encourage authors to test the relevance of their key words by using them for a database search and comparing the results with the topic of their own paper.

**Word limits:** In **full papers**, individual sections should be no longer than Abstract 250

words, Introduction 500 words, Discussion 1500 words, Conclusion 150 words. Materials and Methods and Results sections should be concise but there is no formal word limit.

**Headings:** Papers must include the major headings Abstract, Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgments, and References. Include subheadings as appropriate. Review articles must contain Abstract and Introduction, with subsequent headings and subheadings as appropriate.

### *Introduction*

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results. Material and methods Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described. Results should be clear and concise.

### *Discussion*

This should explore the significance of the results of the work, not repeat them. Avoid extensive citations and discussion of published literature.

### *Conclusions*

Present the conclusions of the study in a short Conclusions section.

**Highlights** Highlights are optional yet highly encouraged for this journal, as they increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the examples here: [example Highlights](#). Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

The Graphical Abstract is optional for research articles, but mandatory for reviews. GAs should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership online. Graphical abstracts should be submitted as a separate file in the online submission system. Refer to the following website for more

information <https://www.elsevier.com/graphicalabstracts>

### *Abbreviations*

Abbreviations must be explained the first time they are used, both in the Abstract and again in the main text.

Abbreviations used as names of cell lines do not need to be explained, but the species and tissue of origin should be made clear in text the first time the cell line is mentioned. Examples: "the human colonic adenocarcinoma cell line Caco-2" or "the porcine renal endothelial cell line LLC-PK1".

### *Acknowledgements*

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.). Please note that funding information must appear under the Acknowledgments heading.

### *Formatting of funding sources*

List funding sources in this standard way to facilitate compliance to funder's requirements: Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa]. It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding. If no funding has been provided for the research, it is recommended to include the following sentence: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

### *Footnotes*

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors build footnotes into the text, and this feature may be used. Should

this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article.

### **Artwork** Electronic artwork General points

- Make sure you use uniform lettering and sizing of your original artwork.
- Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Indicate per figure if it is a single, 1.5 or 2-column fitting image.
- For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
- Please note that individual figure files larger than 10 MB must be provided in separate source files.

A detailed guide on electronic artwork is available.

**You are urged to visit this site; some excerpts from the detailed information are given here.**

### *Formats*

Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below): EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.

TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.

TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.

TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.

### **Please do not:**

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
- Supply files that are too low in resolution.
- Submit graphics that are disproportionately large for the content.



**Color artwork**

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS(or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. Please indicate your preference for color: in print or online only. Further information on the preparation of electronic artwork.

*Figure captions*

Ensure that each illustration has a caption. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

*References*

Citation in text Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

*Reference links*

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly

encouraged.

A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. *Journal of Geophysical Research*, <https://doi.org/10.1029/2001JB000884>. Please note the format of such citations should be in the same style as all other references in the paper.

### *Data references*

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

### *Reference management software*

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley. Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. More information on how to remove field codes from different reference management software.

### *Reference formatting*

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/ book title, chapter title/article title, year of publication, volume

number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

### *Reference style*

**Text:** Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given. Example: ' as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result ....'

**List:** Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

### *Examples:*

Reference to a journal publication:

[1] J. van der Geer, J.A.J. Hanraads, R.A. Lupton, The art of writing a scientific article, *J. Sci. Commun.* 163 (2010) 51–59. <https://doi.org/10.1016/j.Sc.2010.00372>. Reference to a journal publication with an article number:

[2] J. van der Geer, J.A.J. Hanraads, R.A. Lupton, 2018. The art of writing a scientific article. *Heliyon.* 19, e00205. <https://doi.org/10.1016/j.heliyon.2018.e00205>. Reference to a book:

[3] W. Strunk Jr., E.B. White, *The Elements of Style*, fourth ed., Longman, New York, 2000. Reference to a chapter in an edited book:

[4] G.R. Mettam, L.B. Adams, How to prepare an electronic version of your article, in: B.S. Jones, R.Z. Smith (Eds.), *Introduction to the Electronic Age*, E-Publishing Inc., New York, 2009, pp. 281–304. Reference to a website:

[5] Cancer Research UK, Cancer statistics reports for the

[6] M. Oguro, S. Imahiro, S. Saito, T. Nakashizuka, Mortality data for Japanese oakwilt disease and surrounding forest compositions, *Mendeley Data*, v1, 2015. <https://doi.org/10.17632/xwj98nb39r.1>. Reference to software:

[7] E. Coon, M. Berndt, A. Jan, D. Svyatsky, A. Atchley, E. Kikinzon, D. Harp, G. Manzini, E. Shelef, K. Lipnikov, R. Garimella, C. Xu, D. Moulton, S. Karra, S. Painter,

E. Jafarov, S. Molins, Advanced Terrestrial Simulator (ATS) v0.88 (Version 0.88), Zenodo, March 25, 2020. <https://doi.org/10.5281/zenodo.3727209>.

## **Video**

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

## **Data visualization**

Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions here to find out about available data visualization options and how to include them with your article.

## **Supplementary Material**

Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in

Microsoft Office files as these will appear in the published version. Life Sciences requires submission of the whole uncropped images of the original western blots in triplicate that contributed to the quantitative analysis, from which figures have been derived. Please submit as Supplementary Figure(s). **Please note that this is mandatory when western blots are shown.** Please see Example of original western blot for three repeats.

## Research data

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project. Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.

### *Data linking*

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page.

For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

### *Mendeley Data*

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to Mendeley Data. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the [Mendeley Data for journals page](#).

### *Data in Brief*

You have the option of converting any or all parts of your supplementary or additional raw data into a data article published in Data in Brief. A data article is a new kind of article that ensures that your data are actively reviewed, curated, formatted, indexed, given a DOI and made publicly available to all upon publication (watch this [video](#) describing the benefits of publishing your data in Data in Brief). You are encouraged to submit your data article for Data in Brief as an additional item directly alongside the revised version of your manuscript. If your research article is accepted, your data article will automatically be transferred over to Data in Brief where it will be editorially reviewed, published open access and linked to your research article on ScienceDirect. Please note an open access fee is payable for publication in Data in Brief. Full details can be found on the [Data in Brief website](#). Please use this [template](#) to write your Data in Brief data article.

### *MethodsX*

You have the option of converting relevant protocols and methods into one or multiple MethodsX articles, a new kind of article that describes the details of customized research methods. Many researchers spend a significant amount of time on developing methods to fit their specific needs or setting, but often without getting credit for this part of their work. MethodsX, an open access journal, now publishes this information in order to make it searchable, peer reviewed, citable and reproducible. Authors are encouraged to submit their MethodsX article as an additional item directly alongside the revised version of their manuscript. If your research article is accepted, your methods article will automatically be transferred over to MethodsX where it will be editorially reviewed. Please note an open

access fee is payable for publication in MethodsX. Full details can be found on the MethodsX website. Please use the methodstemplate or protocol template to prepare your MethodsX article.

### *Data statement*

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the Data Statement page.

## **AFTER ACCEPTANCE**

### *Online proof correction*

To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

## **Offprints**

The corresponding author, at no cost, will be provided with a PDF file of the article via e-

mail. The PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use.

### **AUTHOR INQUIRIES**

Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also check the status of your submitted article or find out when your accepted article will be published.



## ANEXO B – Aprovação do Comitê de Ética

25/05/2022 11:15

Certificado

### UNOESTE - Universidade do Oeste Paulista

PRÓ-REITORIA DE PESQUISA E PÓS-GRADUAÇÃO

PPG - Programa de Pesquisa de Pós-Graduação  
PEIC - Programa Especial de Iniciação Científica

## Parecer Final

Declaramos para os devidos fins que o Projeto de Pesquisa intitulado "ANÁLISE DA DYSPHANIA AMBROSIOIDES COMO AGENTE PROTETOR DA PERDA DE MASSA ÓSSEA", cadastrado na Coordenadoria de Pesquisa, Desenvolvimento e Inovação (CPDI) sob o número nº 7249 e tendo como participante(s) LUDMILA PANTAROTO LIMA RIBEIRO (discente), ELLEN FERNANDA TORRIANI DA SILVA (discente), TAIS MIRANDA DA CONCEICAO AMARO (discente), CARLOS JOSÉ LEOPOLDO CONSTANTINO (participante externo/voluntário), WILSON ROMERO NAKAGAKI (orientador responsável), foi avaliado e APROVADO pelo COMITÊ ASSESSOR DE PESQUISA INSTITUCIONAL (CAPI) e COMISSÃO DE ÉTICA USO DE ANIMAIS (CEUA) da Universidade do Oeste Paulista - UNOESTE de Presidente Prudente/SP.


Este Projeto de Pesquisa, que envolve a produção, manutenção e/ou utilização de animais pertencentes ao filo Chordata, subfilo Vertebrata (exceto o homem), para fins de pesquisa científica, encontra-se de acordo com os preceitos da Lei nº 11.794, de 8 de Outubro de 2008, do Decreto nº 6.899, de 15 de Julho de 2009, e com as normas editadas pelo Conselho Nacional de Controle da Experimentação Animal (CONCEA), tendo sido APROVADO em reunião realizada em 11/02/2022.


Vigência do projeto: 05/2022 a 04/2024.

#### ANIMAL VIVO

Espécie/Linhagem/Raça	Nº de Animais	Peso	Idade	Sexo	Origem
Rattus norvegicus (Wistar)	40	200 gramas	1 meses	F	Cemib / Unicamp

Presidente Prudente, 12 de Maio de 2022.

  
Prof. Dr. Jair Rodrigues Garcia Jr.  
Docente Responsável pela CPDI

  
Prof. Dr. Felipe Rydygier de Ruediger  
Coordenador da CEUA - UNOESTE

Coordenadoria de Pesquisa, Desenvolvimento e Inovação – CPDI – 18 3229-2079 – cpdi@unoeste.br  
Comitê de Ética em Pesquisa – CEP – 18 3229-2079 – cep@unoeste.br  
Comissão de Ética no Uso de Animais – CEUA – 183229-2079 – ceua@unoeste.br

valide este documento em [www.unoeste.br/sgp](http://www.unoeste.br/sgp) informando o código de segurança 0298199d0b8782963385e815bf7b057c